Francis Knuettel II 4/A
4/A · Pelthos Therapeutics Inc. · Filed Apr 1, 2026
Research Summary
AI-generated summary of this filing
Pelthos (PTHS) CFO Francis Knuettel Receives RSU Award
What Happened
Francis Knuettel II, Pelthos Therapeutics' Chief Financial Officer (also Treasurer & Secretary), received a grant of 33,472 restricted stock units (RSUs) on July 2, 2025. The grant was reported as an award/acquisition at $0.00 per share (no cash paid). This Form 4 is an amendment to report the grant in Table I; the original grant had been reported previously in Table II.
Key Details
- Transaction date: July 2, 2025. Form 4 filed as an amendment on April 1, 2026. (This amendment indicates the filing was updated after the original filing.)
- Transaction type/code: A = Award/Grant (RSUs). Price reported: $0.00; total reported acquisition value = $0.
- Shares granted: 33,472 RSUs (each RSU represents the right to one share of common stock upon settlement). Amounts adjusted for a 1-for-10 reverse stock split effective July 1, 2025.
- Vesting: One-third vests on July 2, 2026; remaining two-thirds vest in equal quarterly installments over the following two years, subject to continued service.
- Ownership notes: Mr. Knuettel is manager of Camden Capital LLC and co-trustee of the Lara Knuettel Revocable Trust; he may be deemed to beneficially own shares held by those entities but disclaims ownership except to his pecuniary interest.
- Filing note: This is an amended Form 4 (Exhibit 24 — Power of Attorney attached). The amendment was filed several months after the grant date.
Context
RSU grants are compensation awards that vest over time and are typically settled in company stock; they do not require out-of-pocket purchase by the insider. Because this filing reports a grant (not a purchase or sale), it does not, by itself, signal immediate buying or selling interest. The late amendment means the reported detail was updated after the original submission—retail investors should consider timing when using insider filings to assess recent insider activity.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2025-07-02+33,472→ 33,472 total
- 10,000(indirect: By LLC)
Common Stock
[F3] - 12,816(indirect: By Trust)
Common Stock
[F4][F3]
Footnotes (4)
- [F1]Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.
- [F2]The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.
- [F3]Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.
- [F4]Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.